Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 7/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carpipramine SCHEMBL29913255 | 1.00 | DRD3 (1.00) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL27478838 | 1.00 | DRD3 (1.00) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL969084 | 0.99 | DRD3 (0.98) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL7353292 | 0.99 | DRD3 (0.98) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL365672 | 0.99 | DRD3 (0.98) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL969082 | 0.98 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL29356300 | 0.98 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL17747956 | 0.98 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL17747957 | 0.98 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL1648924 | 0.97 | DRD3 (0.94) | DRD3CHRM2CHRM1ADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12310974-B1 | Method of treating post-traumatic stress disorder with carpipramine | AVICENNE INVEST, S.A. (LU) | 2025-05-27 | — | — | US | claimed |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-07-13 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0669128-B1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL (JP) | 2000-01-05 | — | — | EP | claimed |
| US-5871778-A | Sustained release microsphere preparation containing antipsychotic drug | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-02-16 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | claimed |
| EP-0669128-A1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-08-30 | — | — | EP | claimed |
| US-4956362-A | Use of carpipramine for the treatment of anxiety and sleep disorders | Rhone-Poulenc Sante, a French Body Corporate (FR) | 1990-09-11 | — | — | US | claimed |
| EP-0374042-A2 | Use of carbipramine in the preparation of a medicament for the treatment of anxiety and sleeping disorders | RHONE-POULENC SANTE (FR) | 1990-06-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310974-B1 | Method of treating post-traumatic stress disorder with carpipramine | SLC6A2, FKBP4, CRH | DRD3 258/4885CHRM2 3483/4885CHRM1 4121/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | DRD3 829/4885CHRM2 123/4885CHRM1 269/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | DRD3 4793/4885CHRM2 4037/4885CHRM1 4551/4885 |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | SLC6A3, SLC6A2, SNCA | DRD3 208/4885CHRM2 2864/4885CHRM1 2273/4885 |
| US-20230218623-A1 | SALTS OF NEUROCEUTICALS AND USES THEREOF | SLC1A2, GABRA6, GABRA2 | DRD3 2212/4885CHRM2 663/4885CHRM1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.